Cargando…
Durability of Sustained Virologic Response and Improvement of Fibrosis Markers after Daclatasvir and Asunaprevir Treatment in Genotype 1b Hepatitis C Virus-Infected Patients: a Real Life and Multicenter Study
BACKGROUND: The long-term data with direct acting antiviral agents were rare. This study investigated the durability of a sustained virologic response (SVR) and the improvement of fibrosis after daclatasvir and asunaprevir (DCV/ASV) treatment in genotype 1b (GT1b) hepatitis C virus (HCV)-infected pa...
Autores principales: | Shin, Seung Kak, Lee, Jin-Woo, Ra, Hannah, Kwon, Oh Sang, Shin, Jong-Beom, Jin, Young-Joo, Lee, Sangheun, Han, Ki Jun, Kim, Young Nam, Kim, Tae Hun, Kim, Yun Soo, Kim, Ju Hyun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Academy of Medical Sciences
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6813423/ https://www.ncbi.nlm.nih.gov/pubmed/31650719 http://dx.doi.org/10.3346/jkms.2019.34.e264 |
Ejemplares similares
-
Prognosis of Patients with Chronic Hepatitis C Genotype 1b Infection Treated Using Daclatasvir/Asunaprevir after Sustained Virologic Response: A 6-Year Multicenter Prospective Observational Study
por: Yoon, Jae-Hyun, et al.
Publicado: (2023) -
Efficacy and Safety of Daclatasvir and Asunaprevir in Patients with Hepatitis C Virus Genotype 1b Infection on Hemodialysis
por: Lee, Byung Seok, et al.
Publicado: (2019) -
Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection
por: Nam, Hee Chul, et al.
Publicado: (2016) -
Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world
por: Oh, Jae Young, et al.
Publicado: (2019) -
Daclatasvir Plus Asunaprevir for Chronic HCV Genotype 1b Infection
por: Kumada, Hiromitsu, et al.
Publicado: (2014)